Published in Gene Therapy Weekly, April 13th, 2000
They evaluated "recombinant adenoassociated virus vector encoding interleukin-l receptor antagonist (rAAV-IL-1Ra) complementary DNA for its potential in the treatment and prevention of lipopolysaccharide (LPS)-induced arthritis," stated R.Y. Pan and colleagues, National Defense Medical Center, Taiwan.
Pan et al. published the results of their study in the journal Arthritis and Rheumatism ("Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.